SCA
ACAD icon

SAC Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

SAC Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,153,694
Closed -$28.1M – 11
2014
Q1 		$28.1M Buy
1,153,694
+982,634
+574% +$24.9M 0.15% 186
2013
Q4 		$4.28M Buy
171,060
+13,235
+8% +$312K 0.02% 527
2013
Q3 		$4.33M Sell
157,825
-43,606
-22% -$912K 0.02% 555
2013
Q2 		$3.66M Buy
+201,431
New +$2.77M 0.02% 592

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SAC Capital Advisors's ACAD Position: Q2 2014 in Review

SAC Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2014, closing a stake of 1,153,694 shares — an estimated $28.1M sold.

SAC Capital Advisors first reported a position in ACAD in Q2 2013 and held it in 4 quarters. The position peaked at $28.1M in Q1 2014. 160 funds tracked by Wall St. Rank hold ACAD as of Q2 2014.

  • SAC Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 1,153,694 Acadia Pharmaceuticals shares in Q2 2014, an estimated $28.1M.
  • SAC Capital Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Acadia Pharmaceuticals position peaked at $28.1M in Q1 2014.
  • 160 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.